International Immunocompromised Host Society 22nd Symposium

Annual Congress Swiss Society for Allergology and Immunology

«Infection and immunity - Are you competent?»

8 - 11 SEPTEMBER 2022
Congress Center Basel, Switzerland
SCIG treatment for lin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.


Cuvitru® – tailoring SCIG treatment for the individual needs of your patients

Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.

Cuvitru® Succinct Statement: Cuvitru® – tailoring SCIG treatment for the individual needs of your patients.

1. Prof. Mike Recher, MD
University Hospital Basel & University of Basel
2. Prof. Hans H. Hirsch, MD, MSc
University of Basel & University Hospital Basel

SSAI & ICHS Joint Meeting 2022, Basel, 8-11 September 2022 Invitation

We are delighted to invite you to the Annual Congress of the Swiss Society for Allergology and Immunology (SSAI) and to the 22nd Symposium of the International Immunocompromised Host Society (ICHS) that will take place as a joint conference in September 8 -11, 2022 at the Congress Center in Basel, Switzerland.

We count on your active participation, presence and support to make this meeting an outstanding interactive event of multidisciplinary excellence.

Together with the members of the Local, the National and the International Scientific Board and the Organizing Committee, we have developed an appealing program to cover the state-of-the art of clinical practice, and to provide a unique forum of discussion which integrates the most recent international developments in clinical, translational, and basic research in academic, clinical and pharmaceutical organisations.

Cheering the motto of «Infection and immunity - Are you competent?», we are looking forward to welcoming you and your colleagues, peers, friends and professional collaborators to Basel in September 2022 and to an exciting Congress.

With kind regards

Prof. Mike Recher, MD
University Hospital Basel & University of Basel

Prof. Hans H. Hirsch, MD, MSc
University of Basel & University Hospital Basel
### PROGRAM OVERVIEW – THURSDAY, 08 SEPTEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Montreal</th>
<th>Singapore</th>
<th>Sydney</th>
<th>Osaka/Samarkand</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Color legend:**
- **SSAI SESSIONS**
- **ICHS SESSIONS**
- **JOINT SESSIONS**
- **INDUSTRY SYMPOSIA**

### PROGRAM OVERVIEW – FRIDAY, 09 SEPTEMBER

<table>
<thead>
<tr>
<th>Time</th>
<th>Montreal</th>
<th>Singapore</th>
<th>Sydney</th>
<th>Osaka/Samarkand</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Color legend:**
- **SSAI SESSIONS**
- **ICHS SESSIONS**
- **JOINT SESSIONS**
- **INDUSTRY SYMPOSIA**
## PROGRAM - THURSDAY, 08 SEPTEMBER 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Registration</td>
</tr>
<tr>
<td>16:00 – 16:05</td>
<td>Singapore Welcome to Basel - welcome to the joint meeting of ICHS and SSAI Hans H. Hirsch, President ICHS / Mike Recher, Congress-President SSAI</td>
</tr>
<tr>
<td>16:05 – 16:30</td>
<td>Infection and immunity: Patient’s perspective Franziska Riner, Lenzburg (CH) / Stefan Eggimann, Küsnacht am Rigi (CH)</td>
</tr>
<tr>
<td>16:30 – 18:00</td>
<td>Singapore Plenary Session 1: Infection and immunity – Are you competent? Chairs: Hans H. Hirsch, Basel (CH) / Mike Recher, Basel (CH)</td>
</tr>
<tr>
<td>18:00 – 18:45</td>
<td>Evening Reception (Industry Exhibition)</td>
</tr>
</tbody>
</table>

## PROGRAM - FRIDAY, 09 SEPTEMBER 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Registration and Room Finding</td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Montreal MEET THE EXPERT 1: Clinical and diagnostic considerations in immunocompetent vs immunodeficient patients (case-based) When Imaging goes viral…Focus on Corona, CARVs and CMV Jens Bremerich, Basel (CH) Clinical, diagnostic and functional integration: The lung expert’s view Daiana Stolz, Basel (CH)</td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Singapore MEET THE EXPERT 2: Epidemiology and management of infections with new therapies in heme-onc and HCT (case-based) The new –nib on the block Benjami W. Teh, Melbourne (AUS) The new block on the -mab Johan Maertens, Leuven (B)</td>
</tr>
</tbody>
</table>

### References

High-throughput and high-dimensional flow cytometry
CyTOF XT. Simply XTraordinary.
Learn more: fluidigm.com

Current and future directions for the management of invasive fungal infections in immunocompromised patients
Friday 9 September 2022, 17:15-18:45 CEST
Singapore room, Congress Center Basel, Switzerland

Dr Samir Agrawal
Queen Mary University of London, UK
Professor Russell Lewis
University of Bologna, Italy
Professor José María Aguado
Universidad Complutense de Madrid and Hospital Universitario 12 de Octubre, Madrid, Spain
Professor Thierry Calandra
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

<table>
<thead>
<tr>
<th>Time (CEST)</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15</td>
<td>Welcome and introduction</td>
<td>Dr Samir Agrawal</td>
</tr>
<tr>
<td>17:25</td>
<td>Importance of PK/PD: optimising antifungal dosing</td>
<td>Professor Russell Lewis</td>
</tr>
<tr>
<td>17:45</td>
<td>Key challenges in the clinical management of invasive candidiasis: the value of a patient-tailored approach</td>
<td>Professor José María Aguado</td>
</tr>
<tr>
<td>18:05</td>
<td>Addressing unmet needs of the current treatment paradigm: novel antifungals in development</td>
<td>Professor Thierry Calandra</td>
</tr>
<tr>
<td>18:25</td>
<td>Q&amp;A session and panel discussion</td>
<td>All</td>
</tr>
</tbody>
</table>

18:40 Meeting close

Non-promotional integrated scientific symposium at ICHS organised by Mundipharma
For healthcare professionals only
SciA-AFN-2200019 | Date of preparation: June 2022

08:00 – 08:50
Sydney
MEET THE EXPERT 3:
Immediate type allergy – Meet the Allergologist

Food Allergy, what’s new?
Barbara Ballmer, St. Gallen (CH)
Understanding antibiotic allergy
Kathrin Scherer Hofmeier, Aarau (CH)

08:00 – 08:50
Osaka/Samarkand
MEET THE EXPERT 4:
Targeted treatment based on molecular mechanisms – Meet the translational immunologist

... in the immunodeficient patient
Mike Recher, Basel (CH)
... in immune-oncology
Heinz Läubli, Basel (CH)

08:50 – 09:00
Room Change

09:00 – 10:00
Singapore
Plenary Session 2: When too little immunity turns bad...
Session dedicated to Dr. Robert Finberg
Chairs: Roy Chemaly, Houston (USA) / Mario Fernández-Ruiz, Madrid (E)

When immunodeficiency looks like infection...
Steven Holland, Bethesda (USA)

When infection looks like immunodeficiency
Jay Fishman, Boston (USA)

10:00 – 10:30
COFFEE BREAK / POSTER WALK (Posters / Industry Exhibition)

10:30 – 11:50
Montreal
Parallel Session 1: Invasive Fungal Infections – Risk, and drugs and personalized medicine
Chairs: Murat Akova, Ankara (TR) / Tobias Hohl, New York (USA)

When things get “IFI” – clinical clues in heme-onc, HCT, and SOT
Nina Khanna, Basel (CH)

Is pre-emptive anti-fungal therapy ready for prime time?
Johann Maertens, Leuven (B)

Genetic risk stratifiers: Pentraxin paradigm and what’s in the pipeline
Pierre-Yves Bochud, Lausanne (CH)

New drugs, new goals, new guidelines
Monica Slavin, Melbourne (AUS)

For Research Use Only. Not for use in diagnostic procedures. Standard BioTools, the Standard BioTools logo, Fluidigm logo, the CyTOF XT logo, CyTOF and CyTOF XT are trademarked Fluidigm Corporation. ©2022 Fluidigm Corporation. All rights reserved. 06/2022
### Vorbeugung der Infektion

- Vor Therapie mit Dupixent eine vorbestehende Helminthose behandeln.
- Bei Infektion während der Behandlung und Nichtansprechen die Dupixent-The  
  - Behandlung einstellen und eine geeignete Behandlung einleiten.

### Besondere Vorsicht

- Patienten auf die Bedeutung von vaskulitischem Hautausschlag, einer Verschlechterung der Lungensymptomatik, Herzkomplikationen
  - bei Hypereosinophilie hinweisen. Ärzte sollten besonders auf das Auftreten dieser Symptome und Zeichen achteten.

### Asthma Patienten

- Patienten mit Asthma sollten Ärzte besonders auf das Auftreten von vaskulitischem Hautausschlag, einer Verschlechterung der Lungensymptomatik, Herzkomplikationen
  - bei Hypereosinophilie hinweisen. Ärzte sollten besonders auf das Auftreten dieser Symptome und Zeichen achteten.

### Add-on-Erhaltungstherapie bei Erwachsenen und Kindern (ab 6 Jahren) mit schwerem Asthma

#### Erwachsene

- Anfangsdosis 600 mg (2 x 300 mg), danach 300 mg alle zwei Wochen (q2w).

#### Kinder und Jugendliche (6–17 Jahren)

- Anfangsdosis 300 mg an Tag 1 und 300 mg an Tag 15, danach 300 mg alle 4 Wochen.

### Dupixent in der Praxis

- Dupixent kann mit oder ohne topische Kortikosteroide verwendet werden.
- Dupixent ist angezeigt als Add-on-Therapie bei atopischer Dermatitis (AD) mit mittelschwerer bis schwerer atopischer Dermatitis (AD) in Kombination mit oraler Kortikosteroidtherapie.

### Kassenzulässigkeit

- Für Patienten mit schwerer atopischer Dermatitis (AD) mit mittelschwerer bis schwerer atopischer Dermatitis (AD) in Kombination mit oraler Kortikosteroidtherapie.

### Nebenwirkungen

- Dupixent kann nicht alleine in der Therapie von Patienten mit atopischer Dermatitis (AD) mit mittelschwerer bis schwerer atopischer Dermatitis (AD) in Kombination mit oraler Kortikosteroidtherapie verordnet werden.

### Dosierung

- Die empfohlene Initialdosis für erwachsene Patienten mit schwerem Asthma beträgt 600 mg (2 x 300 mg), danach 300 mg alle zwei Wochen (q2w).

### Fertigung

- Dupixent (Dupilumab) ist eine monoklonale Antikörper, die subkutan injiziert wird.

### Weitere Informationen

- Alle Referenzen werden von Sanofi auf Anfrage zur Verfügung gestellt.

### Therapieauswahl

- Dupixent ist empfohlen bei Patienten mit schweren atopischen Hauterkrankungen.

### Limitationen

- Dupixent ist nicht sicher und wirksam in der Therapie von Patienten mit schwerer atopischen Dermatitis (AD) mit mittelschwerer bis schwerer atopischer Dermatitis (AD) in Kombination mit oraler Kortikosteroidtherapie.

### Besonderen Vorsicht

- Bei Patienten mit schwerem Asthma, das mit oraler Kortikosteroidtherapie behandelt wird, ist eine Anpassung der Asthma-Behandlung erforderlich.

### Literatur

- American Academy of Dermatology (AAD). Annullierung der Dupixent-The  
  - Behandlung bei Patienten mit schwerer atopischer Dermatitis (AD) mit mittelschwerer bis schwerer atopischer Dermatitis (AD) in Kombination mit oraler Kortikosteroidtherapie.

### Erfahrungen

- Dupixent ist im Vergleich zu Placebo wirksamer und sicherer in der Behandlung von Patienten mit schwerer atopischer Dermatitis (AD) mit mittelschwerer bis schwerer atopischer Dermatitis (AD) in Kombination mit oraler Kortikosteroidtherapie.

### Zusammenfassung

- Dupixent ist eine wirksame und sichere Option für die Therapie von Patienten mit schwerer atopischer Dermatitis (AD) mit mittelschwerer bis schwerer atopischer Dermatitis (AD) in Kombination mit oraler Kortikosteroidtherapie.

### Zulassung

- Zulassungsinhaberin: sanofi-aventis (schweiz) ag, 3, route de Montfl eury, 1214 Vernier, Schweiz.
12:00 – 13:20
Singapore
Industry Lunch Symposium - Supported by Independent Medical Education Grant from Takeda International: When the Troll of Transplantation is out - Cytomegalovirus Diagnosis and Management

- Dancing with the Troll – The lab perspective
  Karoline Leuzinger, Basel [CH]
- Precise and Personalized is Best Against the CMV Troll - The SOT Perspective
  Camille N. Kotton, Boston [USA]
- Taming the CytomegaloBeast: Tools in our Armamentarium – The HCT perspective
  Roy Chemaly, Houston [USA]

12:00 – 13:20
Sydney
Industry Lunch Symposium - CSL Behring AG: Secondary Immunodeficiencies
Chair: Adrian Zürcher, CSL Behring AG

- Burden of infection in SIDs
  Peter Jandus, Geneva [CH]
- SIDs in hemato-oncological situations
  Sacha Zeerleder, Lucerne [CH]
- Where will we see SIDs in the future?
  Kirsten Wittke, Berlin [DE]

13:20 – 13:30
Room Change

13:30 – 15:00
Montreal
Parallel Session 5: THE BEST OF ICHS - CORONA COMPETENCE
Chairs: Nicolas Müller, Zurich [CH] / Malgorzata Mikulska, Genoa [IT]

- Virology
  Roy Chemaly, Houston [USA]
- Solid organ
  Robin Avery, Baltimore [USA]
- HCT
  Monica Slavin, Melbourne [AUS]
- Autoimmunity
  Jose-Maria Aguado, Madrid [E]

13:30 – 15:00
Singapore
Parallel Session 6: Immunity is down - just jack it up
Chairs: Thomas Lehrnbecher, Frankfurt [DE] / Camille N. Kotton, Boston [USA]

- Treating infections with check-point inhibitors?
  Irene Cortese, Bethesda [USA]
- T-cell guided antiviral therapy – ready for use?
  Oriol Manuel, Lausanne [CH]
- Transfer of antigen-specific immune effectors – Just do it!
  Patrizia Comoli, Pavia [IT]
- Energy management in viral infection
  Andreas Bergthaler, Vienna [A]

*Idiopathic Multicentric Castleman Disease (iMCD)
Is a very rare lymphoproliferative disorder with potentially life-threatening symptoms.
Patients with iMCD have a similar poor prognosis as patients with malignant tumor diseases.
The 5-year mortality rate after diagnosis is at 35% with previous therapies and the 10-year mortality rate is even at 60%.

Asthma: filled syringe).


©2022 GSK group of companies or its licensor.

Trademarks are owned by or licensed to the GSK group of companies.

Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyps; EGPA, eosinophilic granulomatosis with polyangiitis; HES, hypereosinophilic syndrome; SEA: severe eosinophilic asthma; VAS, Visual Analogue Scale


Healthcare professionals can request the references mentioned from GlaxoSmithKline AG.


Very common:
- Injection site reactions (acute and delayed) have occurred following administration of Nucala. Pre-existing helminth infections should be treated prior to the administration of Nucala. (Lyophilisate for solution for SC injection, solution for SC injection in pre-filled syringe). GlaxoSmithKline AG, 3053 Münchenbuchsee.

Common:
- Injection site reactions (a.o. pain, erythema, itching, and burning sensation), eczema, urticaria, rash, headache, back pain.

Injury to injection site, local temperature increase, redness, injection site reac-
tions (a.o. pain, erythema, itching, and burning sensation), eczema, urti-
caria, rash, headache, back pain.

Very common:
- Injection site reactions (acute and delayed) have occurred following administra-
tion of Nucala. Pre-existing helminth infections should be treated prior to the administration of Nucala. (Lyophilisate for solution for SC injection, solution for SC injection in pre-filled syringe). GlaxoSmithKline AG, 3053 Münchenbuchsee.

Common:
- Injection site reactions (a.o. pain, erythema, itching, and burning sensation), eczema, urticaria, rash, headache, back pain.

Injury to injection site, local temperature increase, redness, injection site reac-
tions (a.o. pain, erythema, itching, and burning sensation), eczema, urti-
caria, rash, headache, back pain.
### PROGRAM - SATURDAY, 10 SEPTEMBER 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Registration and Room Finding</td>
<td><em>Room Change</em></td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Montreal</td>
<td>MEET THE EXPERT 5: Microbe alarm before transplantation – You’re on call... (Case-based - When to treat, when to defer, when to reject...)</td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Singapore</td>
<td>MEET THE EXPERT 6: Which clinical criteria inform your daily practice?</td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Sydney</td>
<td>MEET THE EXPERT 7: Infection and respiratory allergy - Meet the Aerobiologists</td>
</tr>
<tr>
<td>08:50 – 09:00</td>
<td>Room Change</td>
<td></td>
</tr>
<tr>
<td>09:00 – 10:00</td>
<td>Singapore</td>
<td>Plenary Session 4: Corona and COVID19 in 2022: State-of the-Art in the third pandemic year after start - Session dedicated to Dr. Francisco Marty</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>COFFEE BREAK / POSTER WALK (Posters / Industry Exhibition)</td>
<td></td>
</tr>
<tr>
<td>10:30 – 11:50</td>
<td>Montreal</td>
<td>Parallel Session 9: Bacterial Infections, Immune dysfunction and critical illness</td>
</tr>
</tbody>
</table>

#### Color legend:
- **SSAI SESSIONS**
- **ICHS SESSIONS**
- **JOINT SESSIONS**
- **INDUSTRY SYMPOSIA**

---

**MEET THE EXPERT 8:**

**Next generation immunologists - Meet the Swiss Young Immunologists (SYIS)**

- **Best SYIS abstract 1+2**
  - Chair: Daniela Latorre, Zurich (CH)
  - Microbial triggering of myelin-specific immune cells in the gut drives central nervous system inflammation
    - Lena Siewert, Basel (CH)
  - The emerging role of autoreactive T cells in Guillain-Barré syndrome
    - Lena Sukenikova, Zurich (CH)

- **Best SYIS abstract 3+4**
  - Chair: Sinduya Krishnarajah, Zurich (CH)
  - Generating a Virus-Like Particles based vaccine against IgE
    - Zahra Gharailoo, Bern (CH)
  - A novel Virus-Like Particle platform for the treatment of peanut allergy: mechanistic insights
    - Pascal Krenger, Bern (CH)

---

**MEET THE EXPERT 9:**

**Sepsis State-of-the-Art and what is unique to the immunocompromised host?**

- Thierry Calandra, Lausanne (CH)

---

**MEET THE EXPERT 10:**

**Breaches in defence: catheters, ports and implants post-transplant**

- Paolo Grossi, Varese (IT)

---

**MEET THE EXPERT 11:**

**MDR-bugs in solid organ transplantation: Who is at risk and why?**

- Jose-Maria Aguado, Madrid (E)
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 13:20</td>
<td>Sydney</td>
<td>Industry Lunch Symposium - Moderna:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>mRNA science in response to a pandemic and potential beyond COVID-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Melissa J. Moore, Chief Scientific Officer, Moderna</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protection of immunocompromised patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mike Ison, Chicago (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A trial platform for conducting nested trials of mRNA vaccine efficacy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>for SARS-CoV-2 in immune compromised hosts: The Swiss HIV and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transplant Cohort Studies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heiner C. Bucher, Basel (CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion and Q&amp;A</td>
</tr>
<tr>
<td>12:00 – 13:20</td>
<td>Sydney</td>
<td>Lunch Break - (Posters / Industry Exhibition)</td>
</tr>
<tr>
<td>13:20 – 13:30</td>
<td></td>
<td>Room Change</td>
</tr>
<tr>
<td>13:30 – 15:00</td>
<td>Montreal</td>
<td>Parallel Session 13: Hepatitis Viruses - Direct and Indirect Challenges</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transplantation with HCV – Milestones on the way to the new normal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christine Durand, Baltimore (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatitis E - Virology and clinical manifestations in the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>immunocompetent host</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Darius Moradpour, Lausanne (CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatitis E - Key lessons from Transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nassim Kamar, Toulouse (FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatocellular cancer - mechanisms, personalized profiling and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>therapy approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Markus Heim, Basel (CH)</td>
</tr>
<tr>
<td>13:30 – 15:00</td>
<td>Singapore</td>
<td>Parallel Session 14: Best vaccination for Prevention,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control or Therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: Lindsey R. Baden, Boston (USA) / Maddalena Peghin, Varese (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Pandemic Challenge: Game-changer for respiratory viruses?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Natasha Halasa, Nashville (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Reactivation challenge: CMV and other herpesviruses in</td>
</tr>
<tr>
<td></td>
<td></td>
<td>patients at risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Per Ljungman, Stockholm (SE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The re-infection challenge: lessons from the malaria vaccine field</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Claudia Daubenberger, Allschwil (CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Cure Challenge: Mission impossible or breakthrough for HIV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Francesco Simonetti, Baltimore (USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00 – 15:00</td>
<td>Sydney</td>
<td>Parallel Session 15: Interferons: The good, the bad, the ugly</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The expanding spectrum of autoinflammatory</td>
</tr>
<tr>
<td></td>
<td></td>
<td>interferonopathies and their mimics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Raphaella Goldbach-Mansky, Bethesda (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Priming systemic antiviral immunity by the gut microbiota</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nelson Gekara, Goterborg (SE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>What can we learn about type I interferons from murine models</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Karl Lang, Essen (DE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Type I and Type II Interferons in HLH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jana Pachlopnik, Zurich (CH)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 – 15:15</td>
<td></td>
<td>Room Change</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 – 16:45</td>
<td>Montreal</td>
<td>Industry Afternoon Tea Symposium - Oxford Immunotec:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Examining the immune response using the T-SPOT® technology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Time for Prime Time: T-SPOT.CMV in HCT Recipients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Roy Chemaly, Houston (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical implementation of CMV-specific CMI in solid organ</td>
</tr>
<tr>
<td></td>
<td></td>
<td>transplantation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oriol Bestard, Barcelona (E)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Latent Tuberculosis testing in the Immunocompromised with ELISPOT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Johannes Nemeth, Zurich (CH)</td>
</tr>
</tbody>
</table>
Biotest Switzerland and the Swiss Society for Allergology and Immunology (SSAI) announce the

**Biotest Award 2022, on Understanding and making use of naturally occurring antibodies**

The award of CHF 10,000.- is sponsored by Biotest Switzerland.

Naturally occurring antibodies are often involved in autoimmune, inflammatory and allergic disorders, infections, cancer, and transplant rejections. Such antibodies can promote disease or can be beneficial for patients. Treatment with human plasma products is increasingly helpful, although the mechanisms are not always clear. This award will be given to a scientific basic or clinical study that improves the understanding of disease mechanisms involving naturally occurring antibodies and therapies with human plasma products.

Applicants are asked to provide a cover letter (max 1 page) and the manuscript of their work. All documents should be assembled to one single PDF file, fully searchable (i.e. generated electronically, not by scanning).

The award will be attributed to first and last author(s). They will be invited to present their study at the 25th Allergy Immunology Update Meeting taking place from 27 – 29 January 2023.

The application deadline is the 30 September 2022 for sending your application to Jolanda Trachsel, General Manager SSAI, by email to office@ssai.ch.
Montreal

Parallel Session 17: Technical or Conceptual Game Changers in Laboratory Diagnostics (Swiss Society for Microbiology)

Chairs: Gilbert Greub, Lausanne (CH) / Jean Villard, Geneva (CH)

17:35 – 19:05

What infectious disease clinicians caring for immunocompromised hosts wants from the lab...
Maddalena Peghin, Varese (IT)

Cell-free DNA and Virus replication: New concepts, challenges, and opportunities
Karoline Leuzinger, Basel (CH)

Comprehensive immune phenotyping - the Immunome: for whom, when and why?
Déla Golshayan, Lausanne (CH)

Metagenomics for Immunocompromised
Adrian Egli, Zurich (CH)

Singapore

Parallel Session 18: Infections after Hematopoietic Cell Transplantation (ASTCT and EBMT-sponsored session)

Chairs: Roy Chemaly, Houston (USA) / Rafael De la Cámara, Madrid (E)

17:35 – 19:05

Cytokine release syndrome: CAR-T cells or Sepsis?
Malgorzata Mikulska, Genoa (IT)

Rare Opportunistic Infections after HCT: Nocardiosis and Listeriosis
Dina Averbuch, Jerusalem (IL)

T cell Immunity, T cell Therapy and Viruses: What, when, and how?
Zenia Papanicolaou, New York (USA)

COVID-19 in HCT Recipients: specific immune effectors or antivirals?
Sanjeet Dadhwal, Duarte (USA)

Osaka/Samarkand

SSAI General Assembly

17:35 – 19:05

SSAI General Assembly

19:30 – 23:00 RHINE RIVER CRUISE NETWORKING EVENT

Timetable:
19.30 h Onboarding
20.00 h Departure
23.00 h Arrival

Price:
CHF 150.00
Students:
CHF 75.00

CSL Behring AG, Wankdorfstrasse 10, CH-3014 Bern, www.cslbehring.ch

Think Human
Ersetzen, was fehlt!

CSL Behring ist führend im Bereich der Plasmaprotein-Biotherapeutika. Das Unternehmen setzt sich engagiert für die Behandlung selten und schwerer Krankheiten sowie für die Verbesserung der Lebensqualität von Patienten auf der ganzen Welt ein. Das Unternehmen produziert und vertreibt weltweit eine breite Palette von plasmabasierten und rekombinanten Therapeutika.

CSL Behring ist Ihr Partner in der
• Immunologie • Critical Care • Hämostase • Pneumologie

CytoSorbents™

CytoSorb® Therapy
REGAIN CONTROL
Advanced blood purification in Critical Care Medicine

Removes excessive levels of cytokines, myoglobin and bilirubin which have been shown in studies to help with:

➤ Stabilization of macro- and micro-hemodynamics
➤ Reduction of vasopressor needs in vasoplastic shock
➤ Attenuation of hyperinflammation
➤ Protection of organ function
➤ Toxin removal in liver failure

For an overview of all references and new literature please visit literature.cytosorb-therapy.com

Rhine River Cruise
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>Registration</td>
<td>Registration and Room Finding</td>
<td></td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Montreal</td>
<td>MEET THE EXPERT 9: The mighty mold – mechanisms, manifestations, management (Case-based)</td>
<td>Tobias Hohl, New York (USA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mold biology and pathogenesis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical manifestations and management</td>
<td>Thomas Lehrnbecher, Frankfurt (DE)</td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Singapore</td>
<td>MEET THE EXPERT 10: Don’t crack under pressure... (Case-based)</td>
<td>Adrian Egli, Zurich (CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Do break points: from dilution and diffusion to Maldi-ToF AI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Do break-proof: optimizing treatment of immunocompromised hosts</td>
<td>Malgorzata Mikulska, Genoa (IT)</td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Sydney</td>
<td>MEET THE EXPERT 11: The difficult to vaccine - Meet the vaccinologist</td>
<td>Christoph T. Berger, Basel (CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vaccinations in immunodeficiency</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Allergy to vaccines incl. COVID mRNA vaccines</td>
<td>Yannick Muller, Lausanne (CH)</td>
</tr>
<tr>
<td>08:00 – 08:50</td>
<td>Osaka/Samarkand</td>
<td>MEET THE EXPERT 12: Chronic rhinosinusitis - Meet the ENT specialist</td>
<td>Simona Nicoleta Negoias, Basel (CH)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary chronic rhinosinusitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANCA vasculitis, antibody deficiency etc.: Immunologic causes of chronic rhinosinusitis</td>
<td>Thomas Daikeler, Basel (CH)</td>
</tr>
<tr>
<td>08:50 – 09:00</td>
<td>Room Change</td>
<td>Room Change</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 – 10:00</td>
<td>Plenary Session 5: Novel insights into immune regulation, vaccination and immune therapy&lt;br&gt;Chairs: Malgorzata Mikulska, Genoa (IT) / Manuel Battegay, Basel (CH)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>COFFEE BREAK (Industry Exhibition)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 – 11:50</td>
<td>ABSTRACTS AWARDS: Best Abstracts of Infection &amp; Immunity: What’s new and exciting?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50 – 12:30</td>
<td>CLOSING CEREMONY</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FAREWELL &amp; OUTLOOK&lt;br&gt;Mike Recher, Basel (CH) / Hans H. Hirsch, Basel (CH) / Murat Akova, Ankara (TR)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAVE THE DATE

SAVE THE DATE!
25th Course: Allergy and Immunology Update (AIU)
27–29 January 2023

EVENTFABRIK BERN

BASIC AND TRANSLATIONAL IMMUNOLOGICAL RESEARCH
AUGUST 24-25, 2023
www.congress-info.ch/ssai2023

23RD SYMPOSIUM OF THE INTERNATIONAL IMMUNOCOMPROMISED HOST SOCIETY
SEE YOU IN TURKEY IN 2024

ORGANIZATION

Organization
Prof. Mike Recher, MD, Basel
Prof. Hans H. Hirsch, MD, MSc, Basel

International Scientific Board
José-Maria Aguado, Spain
Murat Akova, Turkey
Robin Avery, USA
Roy Chemaly, USA
Tobias Hoh, USA
Thomas Lehmbacher, Germany
Luis Ostrosky-Zeichner, USA
Monica Slavin, Australia

Local Scientific Board
Christoph Berger, Basel
Daniela Finke, Basel
Luca Bernasconi, Aarau
Adrian Egli, Basel
Karin Hartmann, Basel
Ingmar Heijnen, Basel
Hans H. Hirsch, Basel
Nina Khanna, Basel
Karoline Leuzinger, Basel
Nicolas Müller, Zurich
Andri Rauch, Berne
Mike Recher, Basel
Federica Sallusto, Zurich
Roberto Speck, Zurich
Christian van Delden, Geneva
Jean Villard, Geneva

INFORMATION

Credits
FAMH med. Microbiology 12
FAMH immunologie Allergologie 12
SGH 18
SGMO 18
SGP 18
SSAI 18
SSID 18
SSN 2

Supporting Societies
ESCMID, ESCMID Study group Immunocompromised Hosts (ESGICHI), ESCMID Study group for Respiratory Viruses (ESGREV), SSAI, SSID, UBICO (University of Basel immunology community), SSA (Swiss Society for Aerobiology)

Supporting Organizations and Institutions
City of Basel, University Hospital Basel, University of Basel, NIH.

Professional Congress Organizer
Medworld AG
Andrea Studer / Selina Poletti
Sennweidstrasse 46, 6312 Steinhausen
Phone: +41 41 748 23 00
registration@medworld.ch
www.medworld.ch
SPONSORS & EXHIBITORS

Gold

- Biotest
- GSK
- Pfizer

Silver

- ALK
- AstraZeneca
- moderna
- Om"pharma

Bronze

- CSL Behring
- Cytena
- DSheet
- MediService

Grants

- AlloVir
- ESCMID
- UBiCo
- VIR

Exhibitors

10x Genomics 4
A. Menarini GmbH, Zurich 11
ADR-AC GmbH, Berne 15
Allergopharma AG, Hünenberg 29
Bencard AG, Greifensee 6
Conceptcare GmbH
Careformance, Eschlikon 14
Curiox Biosystems 20
EUROIMMUN Schweiz AG, Kriens 22
MediService AG, Zuchwil 23
Oxford Immunotec, Oxford 21
RÜWAG, Bettlach 32
STEMCELL Technologies, Saint Égrève 9
Thermo Fisher Diagnostics AG, Reinach/Pratteln 27

Additional Support

- ALK-Abelló AG, Wallisellen
- Ansun Biopharma, Inc., San Diego, CA, USA
- CSL Behring AG, Bern
- EUROIMMUN Schweiz AG, Kriens
- GlaxoSmithKline AG, Münchenbuchsee
- MediService AG, Zuchwil
- Mundipharma, Cambridge
- Novartis Pharma Schweiz AG, Rotkreuz
- Octapharma AG, Lachen SZ
- OM Pharma Suisse SA, Villars-sur-Glâne
- Oxford Immunotec, Oxford
- Takeda Pharma AG, Gattikon (Opfikon)

EXHIBITION PLAN

2nd floor
Congress Center Basel

3rd floor
Congress Center Basel

Sponsor booth Buffets
Poster Exhibition
SCIENCE WILL WIN™

**Paxlovid®** (Nirmatrelvir [PF-07321332]) and Ritonavir). Sales Category A. For detailed information, see prescribing information at www.swissmedicinfo.ch.

The drug Paxlovid® is subject to additional monitoring. For more information, see Paxlovid® prescribing information/patient information at www.swissmedicinfo.ch.

Cresemba® (isavuconazole), sales category A; Zavicefta® (ceftazidime/avibactam), sales category A; Zinforo® (ceftaroline), sales category A. For detailed information, see prescribing information at www.swissmedicinfo.ch.